Equities Analysts Set Expectations for TriMas Q4 Earnings

TriMas Co. (NASDAQ:TRS) – Equities researchers at Zacks Research increased their Q4 2024 earnings estimates for TriMas in a research note issued to investors on Monday, January 27th. Zacks Research analyst M. Das now expects that the industrial products company will earn $0.48 per share for the quarter, up from their previous estimate of $0.47. The consensus estimate for TriMas’ current full-year earnings is $1.69 per share. Zacks Research also issued estimates for TriMas’ Q3 2025 earnings at $0.59 EPS, Q4 2026 earnings at $0.50 EPS and FY2026 earnings at $2.10 EPS.

Other analysts also recently issued research reports about the company. BWS Financial reiterated a “buy” rating and issued a $40.00 price objective on shares of TriMas in a research report on Thursday, January 23rd. StockNews.com raised shares of TriMas from a “sell” rating to a “hold” rating in a research note on Wednesday, November 13th.

TriMas Price Performance

Shares of TriMas stock opened at $24.47 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.44 and a current ratio of 2.83. TriMas has a 52-week low of $22.24 and a 52-week high of $28.51. The company has a fifty day moving average of $24.99 and a 200-day moving average of $25.44. The stock has a market capitalization of $992.75 million, a price-to-earnings ratio of 38.23 and a beta of 0.67.

TriMas (NASDAQ:TRS) last released its earnings results on Monday, November 4th. The industrial products company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.14). TriMas had a return on equity of 9.21% and a net margin of 2.93%. The firm had revenue of $229.36 million during the quarter, compared to the consensus estimate of $239.33 million. During the same quarter in the previous year, the firm earned $0.57 EPS. The business’s quarterly revenue was down 2.5% compared to the same quarter last year.

Institutional Investors Weigh In On TriMas

A number of large investors have recently made changes to their positions in TRS. Algert Global LLC increased its position in TriMas by 4.2% during the 2nd quarter. Algert Global LLC now owns 15,779 shares of the industrial products company’s stock valued at $403,000 after purchasing an additional 639 shares during the period. FMR LLC boosted its position in TriMas by 1.7% during the 3rd quarter. FMR LLC now owns 44,082 shares of the industrial products company’s stock valued at $1,125,000 after acquiring an additional 729 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of TriMas by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,461 shares of the industrial products company’s stock worth $982,000 after acquiring an additional 1,227 shares in the last quarter. Inspire Investing LLC lifted its stake in shares of TriMas by 17.4% in the 3rd quarter. Inspire Investing LLC now owns 16,155 shares of the industrial products company’s stock valued at $412,000 after purchasing an additional 2,389 shares during the period. Finally, Creative Planning boosted its position in shares of TriMas by 11.0% during the second quarter. Creative Planning now owns 27,056 shares of the industrial products company’s stock valued at $692,000 after purchasing an additional 2,681 shares in the last quarter. 99.42% of the stock is currently owned by institutional investors.

TriMas Company Profile

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.